SCLN has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
SCLN has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Equity to Asset ratio is calculated as total stockholders equity divided by total asset. SciClone Pharmaceuticals's Total Stockholders Equity for the quarter that ended in Jun. 2017 was $249.9 Mil. SciClone Pharmaceuticals's Total Assets for the quarter that ended in Jun. 2017 was $277.6 Mil. Therefore, SciClone Pharmaceuticals's Equity to Asset Ratio for the quarter that ended in Jun. 2017 was 0.90.
The historical rank and industry rank for SciClone Pharmaceuticals's Equity-to-Asset or its related term are showing as below:
The historical data trend for SciClone Pharmaceuticals's Equity-to-Asset can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
SciClone Pharmaceuticals Annual Data | |||||||||||||||||||||
Trend | Dec07 | Dec08 | Dec09 | Dec10 | Dec11 | Dec12 | Dec13 | Dec14 | Dec15 | Dec16 | |||||||||||
Equity-to-Asset | Get a 7-Day Free Trial | 0.82 | 0.82 | 0.85 | 0.83 | 0.89 |
SciClone Pharmaceuticals Quarterly Data | ||||||||||||||||||||
Sep12 | Dec12 | Mar13 | Jun13 | Sep13 | Dec13 | Mar14 | Jun14 | Sep14 | Dec14 | Mar15 | Jun15 | Sep15 | Dec15 | Mar16 | Jun16 | Sep16 | Dec16 | Mar17 | Jun17 | |
Equity-to-Asset | Get a 7-Day Free Trial | 0.90 | 0.89 | 0.89 | 0.92 | 0.90 |
For the Drug Manufacturers - Specialty & Generic subindustry, SciClone Pharmaceuticals's Equity-to-Asset, along with its competitors' market caps and Equity-to-Asset data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Drug Manufacturers industry and Healthcare sector, SciClone Pharmaceuticals's Equity-to-Asset distribution charts can be found below:
* The bar in red indicates where SciClone Pharmaceuticals's Equity-to-Asset falls into.
Equity to Asset ratio measures the ratios of the portion of the asset owned by shareholders out of the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.
Equity to Asset ratio is calculated by dividing total stockholders equity by total asset.
SciClone Pharmaceuticals's Equity to Asset Ratio for the fiscal year that ended in Dec. 2016 is calculated as
Equity to Asset (A: Dec. 2016 ) | = | Total Stockholders Equity | / | Total Assets |
= | 215.365 | / | 241.898 | |
= | 0.89 |
SciClone Pharmaceuticals's Equity to Asset Ratio for the quarter that ended in Jun. 2017 is calculated as
Equity to Asset (Q: Jun. 2017 ) | = | Total Stockholders Equity | / | Total Assets |
= | 249.867 | / | 277.611 | |
= | 0.90 |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
SciClone Pharmaceuticals (NAS:SCLN) Equity-to-Asset Explanation
Equity to Asset ratio can vary greatly across different industries, as they have different capital structure. A company with smaller Equity to Asset ratio (more leveraged) may have higher ROE % because of the leverage.
For banks, the required minimum Equity to Asset ratio by regulation is 5%. Some stronger banks may have Equity to Asset Ratio of more than 10%.
Thank you for viewing the detailed overview of SciClone Pharmaceuticals's Equity-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.
Richard J Hawkins | director | 950 TOWER LANE, SUITE 900, FOSTER CITY CA 94404-2125 |
Nancy T Chang | director | 101 WESTCOTT, SUITE 603, HOUSTON TX 77007 |
Raymond Anthony Low | director, officer: VP, Finance & Controller | 25 SHADOW TREE CT, DANVILLE CA 94506 |
Wilson Wai-shun Cheung | officer: CFO & Senior VP, Finance | SCICLONE PHARMACEUTICALS, INC., 950 TOWER LANE, SUITE 900, FOSTER CITY CA 94404 |
Jon S Saxe | director | FIRST HORIZON PHARMACEUTICAL CORP, 660 HEMBREE PKWY STE 106, ROSWELL GA 30076 |
Anthony Gregg Lapointe | director | PO BOX 83216, GAITHERSBURG MD 20883-3216 |
Robert King | officer: SVP of Prod. Dev/Supply Chain | 950 TOWER LANE, SUITE 900, FOSTER CITY CA 94404 |
Winnie Wing-kei Tso | other: VP, Finance and Controller | 950 TOWER LANE, SUITE 900, FOSTER CITY CA 94404 |
Stephanie Wong | officer: VP, Finance and Controller | 343 OYSTER POINT BLVD #200, SOUTH SAN FRANCISCO CA 94080 |
Gary Titus | officer: Senior VP Finance & CFO | SCICLONE PHARMACEUTICALS, INC., 950 TOWER LANE, SUITE 900, FOSTER CITY CA 94404-2125 |
Peter Barrett | director | C/O ALNYLAM PHARMACEUTICALS, INC., 300 THIRD STREET, CAMBRIDGE MA 02142 |
Spa Essetifin | 10 percent owner | VIA SUDAFRICA 20, ROME L6 00144 |
Paolo Cavazza | 10 percent owner | VIA TESSERETE, 10, LUGANO V8 V8 |
Farmaceutica Lda Defiante | 10 percent owner | RUA DOS FERREIROS,260, FUNCHAL MADEIRA S1 9000-082 |
Dean S Woodman | director | 233 MOCKINGBIRD TRAIL, PALM BEACH FL 33480 |
From GuruFocus
By gurufocus • 05-26-2009
By gurufocus 10qk • 12-06-2010
By riddock57 riddock57 • 03-12-2015
By gurufocus • 08-07-2009
By gurufocus • 05-26-2009
By gurufocus 10qk • 11-08-2010
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.